Adamas Pharmaceuticals Inc. (NASDAQ:ADMS) finished Wednesday with a subtraction of -$0.01 to close at $8.07, a downside of -0.12 percent. An average of 7,954,100 shares of common stock have been traded in the last five days. There was a gain of $3.40 in the past week. The last 20 days have seen an average of 2,101,285 shares traded, while the 50-day average volume stands at 990,608.
ADMS stock has increased by 77.36% in the last month. The company shares reached their 1-month lowest point of $4.48 on 10/06/21. With the stock rallying to its 52-week high on 02/01/21, shares of the company touched a low of $2.96 and a high of $9.15 in 52 weeks. In spite of this, the price is down -11.80% from the 52-week high.
A Backdoor Way To Profit From Today’s Crypto Bull Market
In any crypto bull market, there's a lot of money to be made.
But what if we told you the best opportunities are not cryptocurrencies themselves… but instead, simply crypto stocks?
This strategy is simply and ridiculously easy.
Here are 6 ways to gain exposure to crypto outside the norm. This is arguably the safest bet you can make.
115 days have passed since Adamas Pharmaceuticals Inc. (ADMS) last reported insider trading activity. Shreedhar Vijay, who is Chief Commercial Officer, most recently acquired $6,200 shares at $5.16 per share on Jun 21. In this transaction, the insider spent $31,983. Director, DEMSKI MARTHA J, disposed of 2,000 shares at a price of $5.17 on Jun 07. The insider now owns more than $10,340 worth of shares. Prior to that, Chief Commercial Officer Shreedhar Vijay went on to Sale 1,051 shares at $5.50 each on Mar 22. An amount of $5,780 was transacted.
Adamas Pharmaceuticals Inc. (ADMS) has a trailing price-to-earnings (P/E) ratio of 23.00 for the broader industry and 32.30 for the sector. The stock’s beta is 2.57. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 4.36.
The quick ratio of Adamas Pharmaceuticals Inc. for the three months ended June 29 was 4.90, and the current ratio was 5.30, indicating that the company is able to meet its debt obligations. On the profitability front, the trailing 12-month gross margin is 97.60% against a 5-year average of 97.6%. Adamas Pharmaceuticals Inc.’s EBITDA margin for the year ending June 29 is -58.17%, while its operating margin for the same period stands at -51.40%. Its gross profit as reported stood at $72.42 million compared to revenue of $74.46 million.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Adamas Pharmaceuticals Inc.’s return on assets was -38.50%, compared to -50.9% over the last five years.
For the three-month period that ended June 29, Adamas Pharmaceuticals Inc. had $2.57 million in cash. In the quarter under review, the net income was up than the previous quarter. The company posted a net income of $21.97 million in the quarter, while revenues of $19.31 million were grew 14.47%. The analyst consensus anticipated Adamas Pharmaceuticals Inc.’s latest quarter earnings to come in at -$0.29 per share, but it turned out to be -$0.27, a 6.90% surprise. For the quarter, EBITDA amounted to -$9.04 million. Shareholders own equity worth $45.6 million.
From a technical analysis perspective, let’s take a brief look at Adamas Pharmaceuticals Inc. (ADMS) price momentum. RSI 9-day as of the close on 13 October was 87.47%, suggesting the stock is Overbought, with historical volatility in this time frame at 281.58%.
As of today, ADMS’s price is $6.67 +72.81% or $3.40 from its 5-day moving average. ADMS is currently trading +73.55% higher than its 20-day SMA and +54.60% higher than its 100-day SMA. However, the stock’s current price level is +52.55% above the SMA50 and +87.24% above the SMA200.
The stochastic %K and %D were 99.26% and 70.44%, respectively, and the average true range (ATR) was 0.49. With the 14-day stochastic at 99.17% and the average true range at 0.42, the RSI (14) stands at 83.00%. The stock has reached 2.30 on the 9-day MACD Oscillator while the 14-day reading was at 2.58.
H.C. Wainwright reiterated its a Buy rating on Adamas Pharmaceuticals Inc. (NASDAQ: ADMS), but raised their price target to $10, indicating a potential price increase of 23.92% for the stock.The consensus rating for Adamas Pharmaceuticals Inc. (ADMS) among analysts is Hold. According to current brokerage recommendations, 0 brokerage firms advise that investors sell ADMS, while 7 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 1 others rate it as a “buy”.
What is ADMS’s price target for the next 12 months?
Analysts predict a range of price targets between $8.00 and $9.10, with a median target of $8.75. Taking a look at these predictions, the average price target given by analysts for Adamas Pharmaceuticals Inc. (ADMS) stock is $8.60.